Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Loss Per Share - Schedule of Antidilutive Common Stock Equivalents (Details) - DiamiR Biosciences Corp. [Member] - shares	6 Months Ended		12 Months Ended
	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024
Stock options [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares	441,750	511,950	511,950	511,950
Restricted stock [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares	88,000	88,000	88,000	88,000
Warrants [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares		29,336		29,336